Nexalin Technologies【NXL】銘柄情報

Nexalin Technologies Inc (NXL) 銘柄情報

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

プレミアム

通貨

0.4565

( -3.39% )

買値

0.4445

売値

0.4699

出来高

28,839

0.4445 日の範囲 0.4671

0.305 52 週間の範囲 2.00

時価総額

9.396M

前日終値

0.4725

始値

0.4671

時刻

0.4572

最終取引時間

00:38:21

財務取引量

US$ 13,023

VWAP

0.451578

平均取引量 (3 か月)

US$ 487,368

発行済株式数

20,581,646

配当利回り

PER

-0.76

1 株当たり利益 (EPS)

-0.47

歳入

275.58k

純利益

-8.33M

Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health epidemic in the United States and China. The company offers Generation 1, an easy-to-administer medical device which utilizes bioelectronic medical technology to trea... Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health epidemic in the United States and China. The company offers Generation 1, an easy-to-administer medical device which utilizes bioelectronic medical technology to treat anxiety, insomnia, and depression without the need for drugs or psychotherapy; and Generation 2 and Generation 3 headset devices for the treatment of depression, substance use disorder, traumatic brain injury, post-traumatic stress disorder, opioid addiction, alcoholism, and chronic pain, as well as alzheimer’s disease, and dementia. Nexalin Technology, Inc. is headquartered in Houston, Texas. 詳細を表示

セクター

Healthcare

業界

Medical Equipment & Supplies

ウェブサイト

www.nexalin.com

本社

Houston, United States

設立

Nexalin Technologies Inc is listed in the Healthcare sector of the ナスダック市場 with ticker NXL. The last closing price for Nexalin Technologies was US$0.47. Over the last year, Nexalin Technologies shares have traded in a share price range of US$ 0.305 to US$ 2.00.

Nexalin Technologies currently has 20,581,646 shares in issue. The market capitalisation of Nexalin Technologies is US$9.40 million. Nexalin Technologies has a price to earnings ratio (PE ratio) of -0.76.

Nexalin Technology Reports Compelling Clinical Trial Results in Brazil to Support Product Launch. Trial Demonstrates 77.8% Anxiety Response Rate and Durable Benefits Across Depression, Insomnia and Quality of Life as Company Advances Brazilian Sales Plan.

Study using Nexalin’s proprietary DIFS™ 15 mA 77.5 Hz treatment platform demonstrated rapid, large-magnitude...

Nexalin Technology Announces Issuance of U.S. Patent Covering Dynamic Frequency Stimulation for Anxiety, Depression and Insomnia

Newly issued U.S. patent expected to provide core intellectual property protection through 2042, further...

Nexalin Technology Secures Key Neurostimulation Legislative Provision & Commends U.S. House-Passed Report Language Expanding Non-Invasive Deep Brain Neurostimulation Research at the Department of Veterans Affairs for Traumatic Brain Injury

U.S. House Appropriations Committee report language directs VA to support additional research evaluating...

Form 8-K - Current report

Nexalin Acquires AI-Integrated Digital Health Platform Behind HALO™ Clarity and Nexalin NeuroCare™ Ahead of Planned FDA Pivotal Trial

HOUSTON, TX, May 19, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. ( (Nasdaq: NXL) (“Nexalin” or the...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nexalin Announces Peer-Reviewed Publication with Neuroimaging Data in Psychotherapy and Psychosomatics Highlighting Brain-Network Effects and Clinical Improvement in Chronic Insomnia

Publication reports statistically significant improvement in sleep quality following treatment with Nexalin’s...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	-0.0735	-13.8679245283	0.53	0.53995	0.4257	299281	0.48441314	CS
4	0.1265	38.3333333333	0.33	0.64	0.305	1489408	0.41745777	CS
12	0.0565	14.125	0.4	0.64	0.305	880276	0.40599379	CS
26	-0.5151	-53.0156442981	0.9716	0.9869	0.305	582529	0.45818047	CS
52	-0.7435	-61.9583333333	1.2	2	0.305	1422571	1.38932685	CS
156	-0.4019	-46.8196644921	0.8584	4.4899	0.2528	962882	1.70980835	CS
260	-2.2435	-83.0925925926	2.7	4.4899	0.2528	803021	1.7011344	CS

NXL - Frequently Asked Questions (FAQ)

What is the current Nexalin Technologies Inc share price?

The current share price of Nexalin Technologies Inc is US$ 0.4565

How many Nexalin Technologies Inc shares are in issue?

Nexalin Technologies Inc has 20,581,646 shares in issue

What is the market cap of Nexalin Technologies Inc?

The market capitalisation of Nexalin Technologies Inc is USD 9.4M

What is the 1 year trading range for Nexalin Technologies Inc share price?

Nexalin Technologies Inc has traded in the range of US$ 0.305 to US$ 2.00 during the past year

What is the PE ratio of Nexalin Technologies Inc?

The price to earnings ratio of Nexalin Technologies Inc is -0.76

What is the cash to sales ratio of Nexalin Technologies Inc?

The cash to sales ratio of Nexalin Technologies Inc is 26.32

What is the registered address of Nexalin Technologies Inc?

The registered address for Nexalin Technologies Inc is 1776 Yorktown, Houston, Texas, 77056

What is the Nexalin Technologies Inc website address?

The website address for Nexalin Technologies Inc is www.nexalin.com

Which industry sector does Nexalin Technologies Inc operate in?

Nexalin Technologies Inc operates in the Medical Equipment & Supplies sector

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

Nexalin Technologies Inc (NXL)

Nexalin Technologies Inc (NXL) 銘柄情報

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

主要統計と詳細

Nexalin Technologies Inc について

NXL 最新ニュース

Nexalin Technology Reports Compelling Clinical Trial Results in Brazil to Support Product Launch. Trial Demonstrates 77.8% Anxiety Response Rate and Durable Benefits Across Depression, Insomnia and Quality of Life as Company Advances Brazilian Sales Plan.

Nexalin Technology Announces Issuance of U.S. Patent Covering Dynamic Frequency Stimulation for Anxiety, Depression and Insomnia

Nexalin Technology Secures Key Neurostimulation Legislative Provision & Commends U.S. House-Passed Report Language Expanding Non-Invasive Deep Brain Neurostimulation Research at the Department of Veterans Affairs for Traumatic Brain Injury

Form 8-K - Current report

Nexalin Acquires AI-Integrated Digital Health Platform Behind HALO™ Clarity and Nexalin NeuroCare™ Ahead of Planned FDA Pivotal Trial

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nexalin Announces Peer-Reviewed Publication with Neuroimaging Data in Psychotherapy and Psychosomatics Highlighting Brain-Network Effects and Clinical Improvement in Chronic Insomnia

Form 8-K - Current report

Nexalin Technology Advances Pivotal Clinical Trial of HALO™ Clarity Toward Q2 2026 Enrollment

Nexalin Advances FDA Alzheimer’s Strategy Following Landmark Leadership Meetings in the U.S. and China

Nexalin Technology Reports Compelling Clinical Trial Results in Brazil to Support Product Launch. Trial Demonstrates 77.8% Anxiety Response Rate and Durable Benefits Across Depression, Insomnia and Quality of Life as Company Advances Brazilian Sales Plan.

Nexalin Technology Announces Issuance of U.S. Patent Covering Dynamic Frequency Stimulation for Anxiety, Depression and Insomnia

Nexalin Technology Secures Key Neurostimulation Legislative Provision & Commends U.S. House-Passed Report Language Expanding Non-Invasive Deep Brain Neurostimulation Research at the Department of Veterans Affairs for Traumatic Brain Injury

Form 8-K - Current report

Nexalin Acquires AI-Integrated Digital Health Platform Behind HALO™ Clarity and Nexalin NeuroCare™ Ahead of Planned FDA Pivotal Trial

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nexalin Announces Peer-Reviewed Publication with Neuroimaging Data in Psychotherapy and Psychosomatics Highlighting Brain-Network Effects and Clinical Improvement in Chronic Insomnia

Form 8-K - Current report

NXL - Frequently Asked Questions (FAQ)

NXL 取引

NXL Discussion

最近閲覧した銘柄

会社情報

ビジネス

人気

アプリを入手

無料で登録してください:

広告を削除する